The analgesic efficacy of morphine varies with rat strain and experimental pain model:implications for target validation efforts in pain drug discovery by Hestehave, Sara et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The analgesic efficacy of morphine varies with rat strain and experimental pain model
Hestehave, Sara; Abelson, Klas S.P.; Brønnum Pedersen, Tina; Munro, Gordon
Published in:
European Journal of Pain (United Kingdom)
DOI:
10.1002/ejp.1327
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Hestehave, S., Abelson, K. S. P., Brønnum Pedersen, T., & Munro, G. (2019). The analgesic efficacy of
morphine varies with rat strain and experimental pain model: implications for target validation efforts in pain drug
discovery. European Journal of Pain (United Kingdom), 23(3), 539-554. https://doi.org/10.1002/ejp.1327
Download date: 03. Feb. 2020
Eur J Pain. 2018;1–16.    |  1wileyonlinelibrary.com/journal/ejp
Received: 14 May 2018 | Revised: 7 September 2018 | Accepted: 10 October 2018
DOI: 10.1002/ejp.1327
O R I G I N A L  A R T I C L E
The analgesic efficacy of morphine varies with rat strain and 
experimental pain model: implications for target validation 
efforts in pain drug discovery
Sara Hestehave1,2 | Klas S. P. Abelson1 | Tina Brønnum Pedersen2 | Gordon Munro3
1Department of Experimental 
Medicine, Faculty of Health and Medical 
Sciences, University of Copenhagen, 
Copenhagen, Denmark
2H. Lundbeck A/S, Valby, Denmark
3Department of Neurology, Danish 
Headache Center, Glostrup Research 
Institute, Glostrup, Copenhagen, Denmark
Correspondence
Sara Hestehave, Department of 
Experimental Medicine, Copenhagen N, 
Denmark.
E-mails: sara.kristensen@sund.ku.dk or 
hestehave_sara@hotmail.com
Funding information
The study was performed at and funded by 
H.Lundbeck A/S, Valby, Denmark.
Abstract
Background: Translating efficacy of analgesic drugs from animal models to humans 
remains challenging. Reasons are multifaceted, but lack of sufficiently rigorous pre-
clinical study design criteria and phenotypically relevant models may be partly re-
sponsible. To begin to address this fundamental issue, we assessed the analgesic 
efficacy of morphine in three inbred rat strains (selected based on stress reactivity 
and affective/pain phenotypes), and outbred Sprague Dawley (SD) rats supplied 
from two vendors.
Methods: Sensitivity to morphine (0.3–6.0 mg/kg, s.c.) was evaluated in the hot 
plate test of acute thermal nociception, the Complete Freund’s Adjuvant (CFA) 
model of inflammatory- induced mechanical hyperalgesia, and in a locomotor motil-
ity assay in male rats from the following strains; Lewis (LEW), Fischer (F344), 
Wistar Kyoto (WKY), and SD’s from Envigo and Charles River.
Results: F344 and SD rats were similarly sensitive to morphine in hot plate and 
CFA- induced inflammatory hyperalgesia (Minimum Effective Dose (MED) = 3.0 mg/
kg). WKY rats developed a less robust mechanical hypersensitivity after CFA injec-
tion, and were less sensitive to morphine in both pain tests (MED = 6.0 mg/kg). 
LEW rats were completely insensitive to morphine in the hot plate test, in contrast to 
the reversal of CFA- induced hyperalgesia (MED = 3.0 mg/kg). All strains exhibited 
a dose- dependent reduction in locomotor activity at 3.0–6.0 mg/kg.
Conclusion: Sensory phenotyping in response to acute thermal and inflammatory- 
induced pain, and sensitivity to morphine in various inbred and outbred rat strains 
indicates that different pathophysiological mechanisms are engaged after injury. 
This could have profound implications for translating preclinical drug discovery ef-
forts into pain patients.
Significance: The choice of rat strain used in preclinical pain research can pro-
foundly affect the outcome of experiments in relation to (a) nociceptive threshold 
responses, and (b) efficacy to analgesic treatment, in assays of acute and tonic in-
flammatory nociceptive pain.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, 
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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1 |  INTRODUCTION
An appreciation of pain enables higher organisms to respond 
appropriately to a spectrum of potentially tissue damaging and 
even life- threatening stimuli. Accordingly, it involves both 
learned and innate components, the understanding of which 
continues to be a source of considerable scientific endeavour 
by the medical research community.
A recognized pillar of preclinical drug development is 
the ability to reliably reproduce experimental findings using 
disease- relevant animal models, both over time, and between 
laboratories (Andrews et al., 2016). As part of this process, 
outbred Wistar and Sprague Dawley (SD) rats are the most 
commonly used rat strains for purposes of experimental test-
ing in medical research (including pain), albeit other out-
bred/inbred strains and selection lines are occasionally used 
(Festing, 2014).
Opioid analgesics such as morphine remain a mainstay of 
treatment for acute moderate to severe pain, despite issues 
related to side effects including dependence, tolerance and 
opioid- induced hyperalgesia (Trang et al., 2015). Notably, 
strain differences in the nociceptive sensitivity to mu- opioid 
agonists in both mice and rats have been reported (Bulka 
et al., 2004; Cook, Barrett, Roach, Bowman, & Picker, 
2000; Freet, Wheeler, Leuenberger, Mosblech, & Grigson, 
2013; Mogil, Chesler, Wilson, Juraska, & Sternberg, 2000; 
Morgan, Cook, & Picker, 1999; Terner, Barrett, Cook, & 
Picker, 2003; Terner, Barrett, Lomas, Negus, & Picker, 
2006; Terner, Lomas, Smith, Barrett, & Picker, 2003). 
Accordingly, it might be expected that the development of 
new pain therapeutics targeting opioid- mediated signalling 
(e.g., biased ligands, and drugs with improved pharmaco-
kinetic/pharmacodynamic properties which slow entry into 
the CNS) in rodent models might be influenced by the rat or 
mouse strain chosen. Moreover, many of the studies detailing 
strain- dependent analgesic effects of opioids have utilized 
behavioural assays that for the most part focused on the use 
of acute nociceptive tests such as tail flick and hot plate, per-
formed in the absence of any overt pathophysiology within 
peripheral or central pain circuits. From a drug development 
perspective, this is puzzling given the consensus of expert 
opinion that improving translation from bench to bedside is 
a fundamental tenet for facilitating the delivery of improved 
analgesic treatments to patients (Andrews et al., 2016; Berge, 
2011; Clark, 2016; Negus et al., 2006; Rice et al., 2008).
Thus, based on the wealth of knowledge accumulated via 
opioid drug research and development, in the current series 
of experiments we chose to use morphine as a prototypical 
analgesic. Initially, we compared its acute analgesic efficacy 
in the absence of injury in SD rats obtained from two separate 
vendors, with three inbred rat strains (Lewis, Fischer F344, 
Wistar- Kyoto) previously reported to differ in analgesic sen-
sitivity to mu- opioids, stress sensitivity and affective states 
(Dhabhar, McEwen, & Spencer, 1993; Pardon et al., 2002; 
Pare, 1994). Thereafter, the same experimental aim was ex-
tended to the same strains in the setting of hindpaw inflam-
matory hyperalgesia produced by the inflammatory algogen 
Complete Freund’s Adjuvant (CFA).
2 |  MATERIALS AND METHODS
2.1 | Animals
For each experiment, a total of 50 male rats per strain 
(Lewis (LEW), Fischer F344 (F344) and Wistar Kyoto 
(WKY) from Harlan/Envigo UK; Hsd:SD from Harlan/
Envigo, Netherlands; and Crl:CD(SD) from Charles River 
Laboratories, Germany) were used. They were aged 7 weeks 
upon arrival, and allowed to acclimatize for 1–2 weeks be-
fore experimental testing. For the CFA experiments, which 
were performed using one strain at a time, an additional 20 
Crl:SD rats were included for intra- asssay control purposes. 
All rats completed the planned experiments except for one 
Hsd:SD rat which was excluded prior to active inclusion in a 
CFA experiment due to the presence of a tooth abscess. F344 
rats were not tested in the locomotor motility assay due to an 
abrupt discontinuation of the strain at the supplier, Envigo.
Experimental protocols for the different testing proce-
dures used at H. Lundbeck A/S were approved by The Animal 
Experiments Inspectorate in Denmark. The entire study was 
performed in accordance with the Danish legislation (Law 
no. 474 of May 15th, 2014 and Ministerial Order no. 12 of 
07/01/2016) regulating experiments on animals, which are in 
compliance with the European Directive 2010/63/EU, and in 
accordance with the International Association for the Study 
of Pain guidelines (Zimmermann, 1983).
Note that we did not investigate an influence of gender 
in the following experiments, which has well- documented 
effects in relation to opioid- mediated analgesia in rodents 
(Cicero, Nock, & Meyer, 1997; Cook et al., 2000; Mogil 
et al., 2000; Terner, Barrett et al., 2003; Terner, Lomas et al., 
2003), due to group size constraints of our study design.
2.2 | Housing
All animals were pair- housed in transparent Techniplast 
polycarbonate macrolone type III- high open cages 
(42.5*26.6*18.5 cm) from Scanbur, Denmark, with aspen 
chips (Tapvei, Estonia) used for bedding. Each cage was 
provided with environmental enrichment consisting of aspen 
wood chewing blocks (S- Bricks from Tapvei, Estonia), 
paper- wool shavings (LBS Biotechnology, UK) for nesting 
material, and red Rat RetreatsTM (Bio- Serv, Flemington, US) 
for hiding, and cages were changed twice a week, but never 
on the days of testing. Food (Altromin 1324, Brogaarden, 
Denmark) and water were available ad libitum with water 
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changed on a weekly basis. The light–dark cycle was 12:12 hr 
with lights on from 06.00 hr; the room temperature was set to 
20°C ± 2°C; and the relative humidity was 55% ± 10%. The 
animals were acclimatized to the surroundings for at least 
1 week after arrival from the vendor, following which they 
were moved to the testing- laboratory at least 3 days prior to 
baseline testing, unless specified otherwise. The animals then 
remained in the testing room throughout the entire study.
3 |  EXPERIMENTAL PROCEDURE
3.1 | Hot plate experiments
We used a hot plate (Ugo Basile Srl 7280, Gemonio, Italy) with 
a pre- set plate temperature of 52.5°C as recommended for rats 
(Bannon & Malmberg, 2007). As soon as the rat was placed 
onto the hot plate the time taken (s) for it to respond by, for ex-
ample licking, shaking or stepping of the hindpaws (Bannon & 
Malmberg, 2007), was measured by the observer (Hestehave, 
Munro, Pedersen, & Abelson, 2017), at which point the rat was 
immediately removed from the hot plate. A cut- off time of 60 s 
was used to minimize the possibility of cutaneous tissue damage.
3.2 | CFA- induced inflammatory 
hyperalgesia
CFA- induced inflammatory hyperalgesia was induced in rats 
as described previously (Kristensen et al., 2017). Individual 
rats received a subcutaneous (s.c.) injection of CFA (CFA; 
Sigma Aldrich, mixed 1:1 in DPBS, 100 μl total volume per 
rat) into the plantar surface of the left hindpaw, while gently 
immobilized in a restraining box. They were then immedi-
ately returned to their home cage for 24 hrs.
Prior to CFA injection, reflex nociceptive responses to 
cutaneous mechanical stimulation were assessed for each 
rat (pre- CFA baseline response). The investigator gently 
restrained the rat and then applied progressively increasing 
mechanical pressure to the mid- plantar region of the left hind-
paw using an electronic version of the Randall Selitto device 
(IITC, Chicago, IL). Pressure application was discontinued 
when the rat attempted to make a reflex hindpaw withdrawal 
(which in some instances was accompanied by vocalization) 
and the paw pressure threshold (g) was recorded. A cut- off 
threshold of 450 g was used to minimize the possibility of 
cutaneous tissue damage. Two additional measures were ob-
tained from adjacent regions of the hindpaw, using approxi-
mately 20–30 s intervals between each measure. The average 
of the three measurements was designated as the mean paw 
pressure threshold. This process was repeated 24 hrs after 
CFA injection (post- CFA baseline) to obtain an index of 
evoked mechanical hyperalgesia (Munro, Erichsen, Rae, & 
Mirza, 2011), and then again 60 min after injection of either 
vehicle or morphine (post- treatment response).
3.3 | Motility assay
Rats were placed individually in transparent macrolone type 
III cages with bedding but no enrichment, similar to their 
home cages, for automated recording of locomotor activity 
during the light phase. Each cage was then placed within a 
holding rack which consisted of four sets of equally spaced 
infrared light sources and photocells located 4 cm above the 
bottom of the cage. The rats were then allowed to move freely 
within the cage for 60 min whereby horizontal movement 
resulted in the infrared light beams being interrupted (Sams- 
Dodd, 1998). The process was recorded continuously using 
custom- designed automated hardware and software (Ellegaard 
Systems A/S, Denmark), with locomotor activity expressed as 
an activity count obtained during the first 15 min of the test.
3.4 | Processing of plasma samples for 
corticosterone measurements
For both hot plate and CFA experiments, trunk blood was 
collected 60 min after testing, into EDTA- tubes. These were 
then centrifuged and plasma collected and stored at −20°C 
until analysis. Plasma corticosterone concentration was 
quantified using a commercial ELISA kit for corticosterone 
(Corticosterone ELISA, EIA- 4164, DRG Instruments GmbH, 
Germany) according to the manufacturer’s instructions.
3.5 | Study design
3.5.1 | Hot plate experiments (Studies 1  
and 2)
An initial study (Study 1) compared analgesic efficacy of 
morphine in SD rats sourced from two different vendors, 
Charles River (Crl:SD) and Harlan (Hsd:SD). Firstly, 50 
male Crl:SD rats were randomly allocated to groups (n = 10 
group) to receive a s.c. injection of either morphine (0.3, 
1.0, 3.0, 6.0 mg/kg) or vehicle (saline). The same protocol 
was used subsequently in an experiment involving 50 male 
Hsd:SD rats, with an additional Crl:SD group (n = 10) 
treated with morphine (3.0 mg/kg) included for purposes of 
intra- assay comparison. All hot plate testing was performed 
between 9.00 and 13.00 hr.
Although routinely used for experimental purposes due 
to an innate ‘depressive- like’ phenotype (Pare, 1994), the in-
bred Wistar Kyoto (WKY) rat also shows distinct changes 
in hypothalamo- pituitary- adrenal (HPA) axis function in re-
sponse to acute and chronic stress paradigms (Pardon et al., 
2002). Similarly, the inbred histocompatible Lewis (LEW) 
and Fischer (F344) strains are often used for experimental 
purposes based on reports that LEW rats display a rela-
tively hypoactive stress response compared to stress hyper- 
responsive F344 rats (Dhabhar et al., 1993).
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Accordingly, a subsequent study (Study 2) was subdi-
vided into two experiments designed to assess (a) the effects 
of repeated hot plate testing on baseline nociceptive sensi-
tivity of inbred and outbred strains, and (b) the analgesic 
efficacy of morphine in inbred strains. Due to the number 
of rats involved in this study, it was blocked into 5 identical 
cohorts of animals comprised of representatives from each 
inbred and outbred strain which all arrived at our facility on 
the same day. Three baseline hot plate tests were performed, 
each separated by 2 days. Two days after the third baseline 
measure, the analgesic efficacy of morphine was assessed. 
The three inbred strains (WKY, LEW and F344) were ran-
domly allocated to five groups (n = 10 per group) for each 
strain to receive either morphine (0.3, 1.0, 3.0, 6.0 mg/kg) or 
vehicle (saline). Outbred strains (Crl:SD and Hsd:SD) were 
randomly allocated to two groups (n = 10 per group) for each 
vendor- supplied strain to receive morphine (3.0 mg/kg) or 
vehicle. The assessment of antinociceptive effects of mor-
phine was carried out using a block design including two rats 
from each group for each strain in five consecutive cohorts 
(meaning 38 animals per cohort), and one cohort of antinoci-
ceptive testing was performed per day, from 08.00 to 11.00 hr 
each day in the exact same manner. At 60 min after testing, 
animals receiving vehicle or 3.0 mg/kg morphine were eutha-
nized by decapitation, and trunk blood was collected for cor-
ticosterone measurements. The remaining test- subjects were 
euthanized with 80% CO2 and 20% O2 for the first 30 s, with 
a gradual increase to 100% CO2 for 7 min.
3.5.2 | CFA- induced inflammatory 
hyperalgesia experiments (Studies 3 and 4)
For the first part of the study (Study 3), in a first experiment, 
only Crl:SD rats were tested. Thereafter, in a second experi-
ment Hsd:SD rats were tested together with a single group 
of Crl:SD rats treated with morphine (3.0 mg/kg, n = 10). 
Subsequently, for Study 4, individual experiments were per-
formed for each inbred strain (LEW, F344 and WKY) with 
two groups of Crl:SD rats (3.0 mg/kg morphine, vehicle, both 
n = 10) included for purposes of intra- assay comparison. For 
each primary strain, rats were randomly allocated to groups 
(n = 10 group) to receive a s.c. injection of either morphine 
(0.3, 1.0, 3.0, 6.0 mg/kg) or vehicle (saline). The magnitude 
of inflammatory hyperalgesia for each rat was calculated 
according to the following equation; [Hyperalgesia = ((pre- 
CFA baseline−post- CFA baseline)/pre- CFA baseline)*100]. 
All CFA experiments were performed between 7.00 and 
11.00 hr during the light phase.
At the end of the experiment, 60 min after testing, all rats 
receiving vehicle or 3.0 mg/kg morphine were euthanized 
by decapitation, trunk blood was collected for corticoste-
rone measurement, and both hindpaws were amputated at the 
exact same anatomical location by the ankle joint (just above 
the tarsal bones). The hindpaws were then weighed with the 
difference between the inflamed versus non- inflamed hind-
paws used as a surrogate index of hindpaw oedema, enabling 
comparison with previously published data from our labora-
tory (Kristensen et al., 2017). The magnitude of paw oedema/
inflammation for each rat was evaluated according to the fol-
lowing equation: [% Oedema = ((Inflamed paw weight−con-
tralateral paw weight)/contralateral paw weight)*100]). The 
remaining test- subjects were euthanized with 80% CO2 and 
20% O2 for the first 30 s, with a gradual increase to 100% 
CO2 for 7 min.
3.5.3 | Exploratory motility
All animals arrived at the facilities on the same day and after 
acclimatization moved to the testing room the day prior to 
the actual test. The locomotor activity testing was divided 
across 5 consecutive experiments comprised of cohorts of 
animals from each strain (LEW, WKY, Hsd:SD, Crl:SD) and 
treatment group, and were performed over 2 days. Rats from 
each strain were randomly allocated to five different groups 
(n = 10 group) to receive a s.c. injection of either morphine 
(0.3, 1.0, 3.0, 6.0 mg/kg) or vehicle (saline). All motility ex-
periments were conducted between 7.00 and 13.00 hr during 
the light phase. At the end of the experiment, animals were 
reused in another unrelated study (unpublished).
3.6 | Drugs and administration
Morphine hydrochloride was obtained from Nomeco 
(Denmark). It was diluted in sterile isotonic saline so that 
the concentration corresponded with a s.c. injection of 5 ml/
kg body weight regardless of treatment group. To perform 
the s.c. injection each rat was placed in the lap of the same 
experienced experimenter (S.H.), and loosely wrapped in 
cotton material to form a restraining cone shape around the 
head and trunk to prevent the rat from turning back on it-
self (Turner, Pekow, Vasbinder, & Brabb, 2011).The s.c. 
injection was then administered in the free skin of the back 
and the rat gently placed back in their home- cage until test-
ing. All doses are expressed as mg/kg body weight of salt. 
Animals were randomly allocated to treatment groups. Drug 
treatments were blinded for the experimenter performing the 
behavioural tests.
3.7 | Data analysis and statistics
Statistical analysis was performed using GraphPad Prism 
version 5 (GraphPad Software, Inc., La Jolla, CA, USA) for 
most analysis, but ANCOVA’s were performed in IBM SPSS 
Statistics, version 24 (IBM Corp.). Although no specific 
power analysis was performed for the current pharmacology 
experiments, appropriate group sizes had previously been 
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estimated in Sigmaplot as a function of the desired effect size 
(approximately 50% reversal to cut- off point), using a signifi-
cance level of 5%, a power of 80% and a SD of approximately 
4 obtained in a pilot study using similar pain assays (Festing 
& Altman, 2002; Kristensen et al., 2017). Statistical com-
parisons of treatment effects (morphine vs vehicle) between 
groups of the same strain were made using one- way ANOVA, 
with Bonferroni’s post test to compare between strain- specific 
groups. Crl:SD groups were included in some trials as an 
intra- assay control, and are highlighted in the grey area of 
the corresponding graphs; however, the control Crl:SD data 
were not included in the one- way ANOVA in order to avoid 
influencing the overall effects of the strain. Accordingly, sta-
tistical comparison between the assay- control Crl:SD vehicle 
and morphine 3.0 mg/kg groups were made using unpaired 
t- tests. The overall strain and drug effects were also analysed 
using two-way ANCOVA (strain*treatment, covariate) with 
either pre- CFA baseline or the average of the three hot plate 
baselines as covariate. Two- way Repeated Measures (RM) 
ANOVA was used to assess the effects of strain and time 
(or CFA injection) for the development of hyperalgesia in 
response to CFA, and for effects of repeated testing in the hot 
plate baselines, (strain * time) followed by Bonferroni post 
test (Figure 2a). Mauchly’s Test of Sphericity was performed 
in SPSS for univariate RM ANOVA’s, and Greenhouse 
Geisser correction was applied when the assumption was 
violated (Figure 1b). For CFA experiments, the magnitude 
of inflammatory hyperalgesia and paw oedema/inflammation 
after CFA- injection for the individual animals was analysed 
by use of one- way ANOVA and Bonferroni post comparison 
test (Figure 2b and c, respectively). Two- way ANOVA was 
used to assess the overall effect of morphine on locomotor 
activity. p < 0.05 was considered statistically significant.
The Minimum Effective Dose (MED) was determined 
as the lowest dose of morphine required to elicit a response 
significantly different from the vehicle response, while the 
Maximum Possible Effect (%MPE) was calculated for the 
highest dose of morphine (6.0 mg/kg) by the following equa-
tion; % MPE = (post- drug latency−vehicle average)*100/
(cutoff−vehicle average).
4 |  RESULTS
4.1 | Influence of strain on acute nociceptive 
responses at baseline and after inflammatory 
injury
As a precursor to assessing the analgesic efficacy of mor-
phine in each rat strain, we needed to establish whether there 
were strain- dependent differences in hindpaw nociceptive 
reflexes to cutaneous thermal or mechanical stimulation. 
Thereafter, based on differences in stress reactivity be-
tween the included strains we hypothesized that they might 
respond differently to repeated nociceptive testing even in 
the absence of injury. Overall, two- way RM ANOVA re-
vealed statistically significant effects of both time (F [2, 
370] = 5.90, p < 0.0001) and strain (F [4, 370] = 14.22, 
p < 0.0001) (Figure 1a) on thermal response latency. 
Moreover, Figure 1a shows this effect was present in each 
strain tested (WKY; F [2, 149] = 5.872, p = 0.0039. LEW; 
F [2, 149] = 5.845, p = 0.0040. F344; F [2, 149] = 11.48, 
p < 0.0001. HSD:SD; F [2, 59] = 10.80, p = 0.0002, 
one- way RM ANOVA), albeit slightly less prominently 
in Crl:SD rats (F [2, 59] = 4.814, p = 0.0137). Notably, 
Crl:SD rats differed from the other strains in two main re-
spects: (a) they were the only strain in which baseline re-
sponses did not vary significantly between tests (b) they 
were consistently more sensitive to noxious thermal stimu-
lation of the hindpaws compared with the other strains.
We further explored the issue of stress sensitivity by 
comparing the impact of vehicle injection on the response 
latency in each strain measured on the day of the pharma-
cological experiment with morphine (Figure 1b). Notice 
F I G U R E  1  Hot plate testing in naïve rats. Development of 
response latency between testing sessions. (a) Effects of repeated 
hot plate testing on baseline response latency (s) in naïve rats from 
each strain. Group sizes; n = 50 for LEW, F344 and WKY, n = 20 for 
Hsd:SD and Crl:SD. Data are presented as mean ± SEM. Statistical 
comparison: two- way RM ANOVA, with Bonferroni’s post test. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs strain- specific Baseline 1.  
(b) Effects of vehicle injection as a novel stressor on response 
latency and comparison with prior baseline latency responses. All 
groups n = 10 rats. Data are presented as mean ± SEM. Two- way 
RM ANOVA with Bonferroni’s post test. *p < 0.05, **p < 0.01, 
***p < 0.001 versus Baseline 1; ++p < 0.01, +++p < 0.001 versus 
Baseline 3
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that Figure 1b only includes testing of the 10 animals of 
each strain receiving vehicle treatment, while Figure 1a in-
cludes baseline tests of all groups prior treatment (n = 50 
for inbred strains, n = 20 for SD- strains). These data 
violated the assumption of sphericity (Mauchly’s Test of 
Sphericity, SPSS), and the results have therefore been cor-
rected by use of Greenhouse- Geisser. Overall, we observed 
a further decrease in response latency with repeated test-
ing (Time: F [2.645, 119] = 27.946, p < 0.0001. Strain: 
F [4, 45] = 8.028, p < 0.0001. Interaction: F [10.579, 
119] = 2.599, p = 0.0038, two- way RM ANOVA). 
Moreover, even when accounting for the effect of re-
peated baseline testing Figure 1b shows that in the stress- 
hyperresponsive strains F344 and WKY, the vehicle 
response was significantly lower (p < 0.001 and p < 0.01, 
respectively, two- way RM ANOVA, Bonferroni post test) 
than the final baseline response. Once again, the Crl:SD 
strain exhibited a more stable response across both baseline 
testing and vehicle injection (Figure 1b).
Next, to simulate facets of injury- induced pathophysiol-
ogy, we injected rats with the inflammatory algogen CFA. 
Figure 2a shows that corresponding pre- CFA and post- CFA 
baselines differed significantly in all strains (F- value for 
time [1, 244] = 1148, p < 0.0001, two- way RM ANOVA), 
indicating the presence of inflammatory- induced hyperalge-
sia. Similarly, two- way RM ANOVA also revealed a signif-
icant effect of strain (F [4, 244] = 48.40, p < 0.0001), and 
a strain*time- interaction, indicating that the CFA- injection/
time had different effects on the various strains (F [4, 
244] = 51.58, p < 0.0001). This allowed a comparison of 
pre- and post- CFA paw pressure thresholds between strains 
to be performed. Accordingly, the pre- CFA paw pressure 
threshold was significantly higher in Crl:SD than all the other 
strains (p < 0.001, Bonferroni post test). Conversely, after in-
duction of inflammation, the post- CFA paw pressure thresh-
old was significantly higher in WKY rats than all the other 
strains (p < 0.05–0.001).
Subsequent normalization of the post- CFA response 
to the pre- CFA response enabled the manifestation of the 
inflammatory pain response to be visualized as “% hyper-
algesia” for each strain (Figure 2b). Again, we observed a 
significant effect of strain (F [4, 244] = 28.85, p < 0.0001, 
one- way ANOVA). Of note, WKY rats displayed only a 
modest hyperalgesic response (25.0 ± 4.6%) compared with 
the other strains (Crl:SD; 67.9 ± 1.5, Hsd:SD; 60.4 ± 2.7, 
LEW; 58.8 ± 2.2, F344; 53.4 ± 3.4%), all p < 0.001 versus 
WKY, one- way ANOVA, Bonferroni post test).
Finally, an index of the inflammatory response per se, 
was obtained by measuring the % paw oedema present at 
the end of the experiment in rats from the morphine 3 mg/
kg and vehicle- treated groups. Although Figure 2c shows 
there was a significant effect of strain on the % paw oedema 
response at this time (F [4, 145] = 5.49, p < 0.0004, one- 
way ANOVA) this did not appear to correlate with the ro-
bustness of hyperalgesia present (Figure 2b). Notably, the 
largest response was obtained in Hsd:SD and LEW strains 
(p < 0.01 vs. Crl:SD, one- way ANOVA and Bonferroni 
F I G U R E  2  Strain differences in response to CFA injection. 
(a) Paw pressure thresholds (g) prior to and 24 hrs after hindpaw 
CFA injection. All groups n = 50, except Hsd:SD, n = 49. Data are 
presented as mean ± SEM. Two- way RM ANOVA with Bonferroni’s 
post test. ***p < 0.001 Pre- versus Post- CFA. (b) Presence of 
inflammatory- induced hyperalgesia (% hyperalgesia) 24 hrs after 
hindpaw CFA injection. All groups n = 50, except Hsd:SD, n = 49. 
*p < 0.05, ***p < 0.001. (c) Hindpaw inflammatory response 
(% oedema formation) induced by CFA injection measured as the 
weight difference between the inflamed paw versus the non- inflamed 
paw. All groups n = 20 except Crl:SD, n = 70. Data are presented 
as mean ± SEM. One- way ANOVA, with Bonferroni’s post test. 
*p < 0.05, **p < 0.01, ***p < 0.001
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post test) with no difference in % paw oedema between 
WKY and Crl:SD strains.
4.2 | Acute analgesic effects of morphine 
in the hot plate test
Dose- dependent antinociceptive effects of morphine (0.3–
6.0 mg/kg, s.c.) treatment were clearly apparent in 4 out of 
5 of the tested strains, albeit the MED and %MPE varied 
(Figures 3–5, and Table 1); note that the data presented in 
these figures reflect experiments performed in hot plate 
studies 1 and 2. Accordingly, a two way ANCOVA of the 
data obtained in Study 2 which utilized a block design to 
comprise rats from all strains demonstrated significant ef-
fects of both treatment (F [4, 170] = 42.443, p < 0.0005) 
and strain (F [4, 170] = 4.373, p < 0.002), and a sig-
nificant interaction between treatment and strain (F [4, 
170] = 5.606, p < 0.0005). The largest effect size was for 
treatment (partial eta squared = 0.5), with F344, Crl:SD and 
Hsd:SD strains all possessing a morphine MED = 3.0 mg/
kg (p < 0.001 (F344 and Crl:SD), p < 0.01–0.001 (Hsd:SD) 
vs. vehicle, one- way ANOVA, Bonferroni’s post test) as 
indicated in Figures 3a and c & 4c. In WKY rats, a higher 
dose of 6.0 mg/kg was required to produce a significant an-
tinociceptive effect (p < 0.001 vs. vehicle), (Figure 5a). In 
contrast, LEW rats were insensitive to the antinociceptive 
effects of morphine (F [4,45] = 2.25, p = 0.0784, one- way 
ANOVA), (Figure 4a).
4.3 | Anti- hyperalgesic effects of morphine 
in rats with CFA- induced inflammation
Figures 3–5 show that s.c. administration of morphine 
(0.3–6.0 mg/kg) produced a robust dose- dependent rever-
sal of CFA- induced hyperalgesia (F [4, 223] = 307.84, 
p < 0.0005, two way ANCOVA with pre- CFA baseline as 
covariate) with a large effect size for treatment (partial eta 
squared = 0.847). There was also a significant effect of strain 
(F [4, 223] = 13.295, p < 0.0005, two way ANCOVA), and 
a significant interaction effect of treatment*strain (F [16, 
223] = 2.671, p < 0.001), but with smaller effect sizes than 
the effect of morphine (partial eta squared = strain: 0.193, and 
F I G U R E  3  Effects of morphine on acute nociceptive pain and CFA- induced hyperalgesia in SD rats obtained from two different vendors. 
Animals were administered either morphine (0.3–6.0 mg/kg, s.c.) or vehicle prior to measuring (a, c) the response latency to thermal stimulation 
(52.5°C) in the hot plate test, or (b, d) effects on paw pressure thresholds (g) using an electronic Randall Selitto device as an index of mechanical 
hypersensitivity. Data are presented as mean ± SEM. The dotted lines in (a, c) indicate pre- injection baselines across the Crl:SD and Hsd:SD 
groups, and in (b, d) baselines across Crl:SD and Hsd:SD groups before (“Pre- CFA”) and 24 hrs after injection (“Post- CFA”) of CFA. As indicated 
in 3a, then the Crl:SD- control strain exhibits a lower baseline/vehicle- response, and comparable response latencies after 3.0 mg/kg for Crl:SD in 
figure a and c. All groups n = 10 rats. Note that the Hsd:SD vehicle and baseline responses in (c) are higher than the corresponding responses for 
Crl:SD rats in (a). This might have potentially masked a significant analgesic effect of 3.0 mg/kg morphine in Crl:SD in (c). One- way ANOVA, 
Bonferroni’s post test. **p < 0.01, ***p < 0.001 versus vehicle
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treatment*strain; 0.161). Moreover, at the level of each individ-
ual experiment, significant effects of morphine treatment were 
detected in all strains (LEW: F [4,45] = 95.30, p < 0.0001, 
WKY: F [4,45] = 56.40, p < 0.0001, F344: F [4,45] = 40.43, 
p < 0.0001, Hsd:SD: F [4,45] = 122.1, p < 0.0001, Crl:SD: F 
[4,45] = 58.08, p < 0.0001, one- way ANOVAs), with a rank 
order of potency ranging from MED = 1–6 mg/kg (Crl:SD > 
Hsd:SD = LEW = F344 > WKY) (Table 1).
Importantly, administration of 3 mg/kg morphine to 
Crl:SD rats for inter- assay control purposes produced ro-
bust antihyperalgesia in each experiment (p < 0.0001 vs. 
strain- specific vehicle, Student’s t- test) (grey area of graphs 
F I G U R E  4  Effects of morphine on acute nociceptive pain and CFA- induced hyperalgesia in Lewis and Fischer (F344) rats. Animals 
were administered either morphine (0.3–6.0 mg/kg, s.c.) or vehicle 60 min prior to measuring (a, c) the response latency to thermal stimulation 
(52.5°C) in the hot plate test, or (b, d) effects on paw pressure thresholds (g) using an electronic Randall Selitto device as an index of mechanical 
hypersensitivity. Data are presented as mean ± SEM. The dotted lines in (a, c) indicate pre- injection baselines across the LEW or F344 groups, and 
in (b, d) baseline across LEW or F344 groups before (“Pre- CFA”) and 24 hrs after injection (“Post- CFA”) of CFA. All groups n = 10 rats. One- way 
ANOVA, Bonferroni’s post test for F344 and LEW groups, Unpaired t- test for Crl:SD- groups. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle
F I G U R E  5  Effects of morphine on acute nociceptive pain and CFA- induced hyperalgesia in Wistar Kyoto rats. Animals were administered 
either morphine (0.3–6.0 mg/kg, s.c.) or vehicle 60 min prior to measuring (a) the response latency to thermal stimulation (52.5°C) in the hot plate 
test, or (b) effects on the paw pressure threshold (g) using an electronic Randall Selitto device as an index of mechanical hypersensitivity. Data are 
presented as mean ± SEM. The dotted lines in (a) indicate pre- injection baselines across WKY groups, and in (b) baseline across WKY groups 
before (“Pre- CFA”) and 24 hrs after injection (“Post- CFA”) of CFA. All groups n = 10 rats. One- way ANOVA, Bonferroni’s post test for WKY 
groups, Unpaired t- test for Crl:SD- groups. *p < 0.05, ***p < 0.001 versus vehicle
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Figures 3–5). We would have preferred to have used a block 
design with individual CFA experiments split into treatment 
groups containing smaller numbers of rats from each strain. 
However, pragmatic reasons dictated the experimental design 
employed herein since we established early on that the ven-
dors could not guarantee availability of test subjects simulta-
neously for such a purpose.
4.4 | Plasma corticosterone levels in hot 
plate and CFA experiments
Glucocorticoids are released in response to stress, and as po-
tent inhibitors of inflammatory processes (Tonelli, Webster, 
Rapp, & Sternberg, 2001) can be used as adjuvants to re-
duce opioid use in various pain conditions. Accordingly, we 
wanted to investigate if any putative strain differences in the 
antinociceptive or anti- hyperalgesic efficacies of morphine 
might be linked to glucocorticoid activity. Note that a limi-
tation to the corticosterone measurements presented here is 
that they were obtained 120 min after injection, in contrast 
to behavioural measures which were obtained 60 min after 
injection (Study 2 & 4). Thus, it is possible that any stress as-
sociated with behavioural handling might have inadvertently 
impacted upon corticosterone measurements.
Figure 6a shows that morphine treatment had no effect on 
plasma corticosterone levels in the different strains, albeit sig-
nificant effects of strain per se were observed (F [4,90] = 7.728, 
p < 0.0001; two- way ANOVA). Accordingly, Bonferroni’s 
post hoc tests detected strain differences between F344 vehicle- 
treated rats compared WKY (p < 0.01), Hsd:SD (p < 0.001) 
and Crl:SD rats (p < 0.05). Similarly, vehicle-treated LEW 
showed significantly higher plasma concentrations than 
Hsd:SD (p < 0.01). The only difference between morphine- 
groups was found between F344 and Hsd:SD (p < 0.01). For 
the CFA study shown in Figure 6b only results from histocom-
patible LEW and F344 are presented (due to the widely ac-
knowledged impact of the immune system on inflammatory 
and associated stress reactivity), together with Crl:SD rats 
T A B L E  1  Comparative efficacy of morphine in different rat strains
Strain
Hot plate CFA LMA CFA- parameters (%)
MED %MPE MED %MPE MED %MPE Hyperalgesia Paw oedema
Crl:SD 3.0 62.7 ± 7.5 1.0 98.9 ± 0.8 3.0 91.1 ± 2.2 67.9 ± 1.5 38.9 ± 1.5
Hsd:SD 3.0 55.4 ± 9.4 3.0 97.9 ± 1.2 3.0 89.7 ± 3.6 60.4 ± 2.7 52.4 ± 3.5
LEW >6.0 8.4 ± 5.1 3.0 97.5 ± 1.6 3.0 84.2 ± 3.8 58.8 ± 2.2 52.8 ± 4.0
F344 3.0 67.6 ± 7.3 3.0 74.5 ± 8.4 – – 53.4 ± 3.4 43.2 ± 4.0
WKY 6.0 45.2 ± 7.3 6.0 84.9 ± 6.2 3.0 94.5 ± 2.7 25.0 ± 4.6 41.1 ± 1.9
Data are presented as MED (Minimum Effective Dose) or as % MPE (Maximum Possible Effect) = (post- drug value − vehicle average)*100/(assay cut- off value − vehi-
cle average) and calculated for the highest dose of morphine (6.0 mg/kg) in each case. The assay cut- off values were LMA = 0, CFA = 450 and hot plate = 60. 
mean ± SEM. CFA, CFA- induced inflammation; LMA, Locomotor activity. Note that LMA was not measured for the F344- strain due to supply issues from the vendor.
F I G U R E  6  Plasma corticosterone levels in hot plate and 
CFA experiments. Plasma corticosterone was measured at 1 hr after 
nociceptive testing, and 2 hrs after s.c. injection of either 3 mg/kg 
morphine or vehicle. (a) Plasma corticosterone levels (nM = nmol/L) 
in hot plate experiments including groups from all strains. Comparing 
vehicle groups, F344 was significantly higher than WKY (p < 0.01), 
Hsd:SD (p < 0.001) and Crl:SD (p < 0.05), and LEW was significantly 
higher than Hsd:SD (p < 0.01), two- way ANOVA with Bonferroni’s 
post test. Following morphine treatment, only Hsd:SD was 
significantly lower than F344 (p < 0.01). (b) Plasma corticosterone 
levels in CFA experiments comparing LEW and F344 rats with Crl:SD 
rats included for inter- assay control purposes. All groups n = 10 
rats. Data are presented as mean ± SEM. Two- way ANOVA and 
Bonferroni’s post test revealed significant difference between vehicle 
and morphine- treated groups of the same strain. ***p < 0.001 versus 
vehicle. Additional post tests also revealed that morphine- treated 
Crl:SD were significantly higher than LEW and F344 (p < 0.01). No 
differences were detected between vehicle groups
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which were included for assay- control purposes. Morphine 
treatment resulted in elevated plasma levels of corticosterone 
(F [1,72] = 29.51, p < 0.0001) and interacted significantly 
with strain (F [3,72] = 3.367, p = 0.0232, two- way ANOVA) 
in CFA rats, indicating that the effect was not similar across 
the different strains. Notably, Bonferroni’s post test indi-
cated that this effect of morphine only occurred in Crl:SD 
rats (p < 0.001 vs. vehicle). Comparison between strains 
showed no differences between vehicle- treated groups, but 
morphine- treated Crl:SD- controls were significantly higher 
than morphine- treated LEW and F344 (both p < 0.01, 
Bonferroni’s post test).
4.5 | Effects of morphine on 
locomotor activity
As indicated in Figure 7a–d, s.c. administration of mor-
phine (0.3–6.0 mg/kg) produced a dose- dependent inhibition 
of activity in all strains included in the experiment (LEW: 
F [4,45] = 45.63, p = <0.0001; WKY: F [4,45] = 30.81, 
p = <0.0001; Hsd:SD: F [4,45] = 43.07, p = <0.0001; 
Crl:SD: F [4,45] = 25.46, p = <0.0001, one- way ANOVA) 
when measured over the first 15 min of the assay proce-
dure. Notably, morphine was equally potent in each strain 
(MED = 3.0 mg/kg, Table 1). Thus, any putative sedative 
or motor- impairing effects of morphine are unlikely to have 
been a primary confounding issue explaining the strain- 
dependent analgesic efficacy of morphine observed in the hot 
plate or CFA experiments.
5 |  DISCUSSION
We have consolidated a number of important experimental 
parameters (e.g., investigator, vendor, rat strain, pain as-
says) which can impact upon the pharmacological outcome 
for a candidate analgesic in the preclinical setting (Chesler, 
Wilson, Lariviere, Rodriguez- Zas, & Mogil, 2002; Lacroix- 
Fralish & Mogil, 2009; Lariviere & Mogil, 2010; Lewejohann 
et al., 2006; Sorge et al., 2014). Our findings revealed strain- 
and vendor- dependent differences in nociceptive thresholds 
and sensitivity to morphine, prior to and after inflammatory 
injury. We believe these observations have important impli-
cations for translating preclinical drug discovery efforts into 
pain patients, as they highlight a limited translational value of 
in vivo data sets when derived from a single animal strain or 
single pain assay alone.
5.1 | Nociceptive thresholds prior to and 
after acute injection or inflammatory injury
For the strains included here, baseline nociceptive thresh-
olds varied considerably depending on the stimulus 
modality. Noxious thermal stimulation of the hindpaws re-
vealed that Crl:SD rats were most sensitive at the first test 
(Crl:SD>Hsd:SD=WKY=LEW=F334). Repeated testing 
then produced an expected decline in baseline response la-
tency, albeit it varied between strains. Subsequently, when 
the final session of baseline nociceptive testing was followed 
by an acute injection of vehicle, sensitizing effects of this 
F I G U R E  7  Effect of morphine on 
locomotor activity. The activity count 
represents the number of horizontal laser 
beams broken by the rat during the first 
15 min of the assay and was measured 
45–60 min after injection of either 
morphine (0.3–6.0 mg/kg, s.c.) or vehicle. 
All groups n = 10 rats. Data are presented 
as mean ± SEM. One- way ANOVA with 
Bonferroni’s post test, significant difference 
compared with vehicle treated group. 
**p < 0.01, ***p < 0.001 versus vehicle
   | 11HESTEHAVE ET Al.
novel stressor on nociceptive thresholds were only seen 
in the stress- responsive F344 and WKY strains (Dhabhar 
et al., 1993; Gomez, Lahmame, de Kloet, & Armario, 1996; 
Sternberg et al., 1989). This latter finding is important in 
light of various studies reporting strain differences wherein 
analgesic efficacy of opioids have been inferred from base-
line rather than vehicle comparisons (Cook et al., 2000; 
Herradon, Morales, & Alguacil, 2003; Herradon, Morales, 
Perez- Garcia, & Alguacil, 2003; Mogil et al., 2000; Morgan 
et al., 1999; Terner, Barrett et al., 2003; Terner, Lomas et al., 
2003; Terner et al., 2006; Vaccarino & Couret, 1995; Vit 
et al., 2006; Woolfolk & Holtzman, 1995).
A positive correlation between thermal and mechanical 
stimuli on hindpaw nociceptive responses has been observed 
in naive male rats representing eight inbred and outbred strains 
(Shir et al., 2001). Thus, we were surprised that Crl:SD rats 
were paradoxically least sensitive to Randall Selitto stimula-
tion of the hindpaw (Crl:SD<Hsd:SD<LEW<WKY=F344). 
Thereafter, following CFA-injection, with the threshold dif-
ference considered as an index of mechanical hyperalgesia 
(Kristensen et al., 2017; Soignier et al., 2011), we observed 
similar responses in all strains, with the exception of WKY 
which developed only a modest hyperalgesia. These findings 
were unexpected based on (a) reports that F344 rats develop 
more robust hyperalgesia than LEW rats in response to acute 
inflammation induced by CFA (Zhang, Lao, Qiao, & Ruda, 
2003), carrageenan (Fecho, Manning, Maixner, & Schmitt, 
2007; Fecho & Valtschanoff, 2006; Juif, Anton, & Hanesch, 
2012) or formalin (Lariviere, Sattar, & Melzack, 2006) (b) in-
creased expression of formalin- induced second phase nocifen-
sive behaviours in WKY versus SD rats (Burke et al., 2010) 
(c) the comparable level of CFA- induced oedema in WKY and 
the other strains in this study. Although handling was transient 
during Randall Selitto testing, differences in stress- reactivity 
and affective state of the various strains (Dhabhar et al., 1993; 
Pardon et al., 2002; Pare, 1994), might theoretically have im-
pacted on nociceptive thresholds as a consequence of stress- 
induced analgesia (Butler & Finn, 2009; Vit et al., 2006) 
or learned helplessness (Pare, 1994; Wu & Wang, 2010). 
Ultimately, sensitivity to nociceptive stimulation at baseline 
does not generalize to a hyper- responsive pain phenotype after 
acute inflammatory injury (Liang et al., 2006).
5.2 | Antinociceptive actions of morphine 
in the hot plate test and analgesic effects in 
CFA- inflamed rats
Acute analgesic effects of opioids in rodent assays of ther-
mal nociception can vary with genotype, gender, stimulus in-
tensity and potency/pharmacokinetics of the opioid in question 
(Cook et al., 2000; Morgan et al., 1999; Terner, Barrett et al., 
2003; Terner, Lomas et al., 2003). Consistent with our find-
ings, LEW rats have been found to be less sensitive to opioids 
compared with Long Evans or SD rats using a tail withdrawal 
assay (Morgan et al., 1999), as well as histocompatible F344 
rats across a number of both nociceptive and non- nociceptive 
behaviours (e.g., tail withdrawal, conditioned place preference 
or conditioned taste aversion) (Cook et al., 2000; Davis, Roma, 
Dominguez, & Riley, 2007; Freet et al., 2013; Morgan et al., 
1999; Terner, Barrett et al., 2003; Terner, Lomas et al., 2003; 
Vaccarino & Couret, 1995). Similarly, WKY rats appear to be 
less sensitive to morphine than SD rats in acute thermal noci-
ceptive assays (Bhargava, Villar, Rahmani, & Larsen, 1992; 
Hoffmann, Plesan, & Wiesenfeld- Hallin, 1998). While these 
observations would simply appear to reflect a general lack of 
sensitivity to opioids within the LEW and WKY strains, this 
concept is not supported by our automated locomotor activity 
data where the mild motor- impairing actions of 3 mg/kg mor-
phine were extremely similar across the strains tested, and in 
agreement with previous observations reported for SD rats 
(Munro, 2009). Unfortunately, we were unable to include F344 
rats in these experiments due to an abrupt discontinuation of 
the strain by the vendor. However, a 3 mg/kg dose of morphine 
would also be expected to impair locomotor activity in F344 rats 
(Sudakov et al., 1993).
To simulate facets of injury- induced pathophysiology, we in-
jected rats with the inflammatory algogen CFA, which sensitizes 
peripheral sensory neurons and drives central hyperexcitability 
changes within dorsal horn pain circuits (Julius and Basbaum, 
2001; Marchand, Perretti, & McMahon, 2005; Schafer, Imai, 
Uhl, & Stein, 1995). As expected morphine reversed inflam-
matory hyperalgesia in each strain albeit with varying potency 
(Fecho et al., 2007; Kristensen et al., 2017). Thereafter, com-
parison with morphine efficacy in hot plate revealed strain- 
dependent differences in opioid- mediated analgesia following 
injury. Multiple studies have shown that inflammatory pain 
and genetics combine to modulate analgesia mediated by opi-
oids in rodents (Chesler et al., 2003; Liang et al., 2006; Mogil, 
Lichtensteiger, & Wilson, 1998). Here, the clearest increase in 
both morphine efficacy and potency in response to CFA injec-
tion was observed in LEW rats, to the extent that they were es-
sentially indistinguishable from the other strains. Interesting in 
itself, this type of strain- dependent analgesia has important im-
plications for the uninitiated investigator from a drug discovery 
perspective in pain.
5.3 | How might analgesic efficacy to 
morphine manifest variously across different 
rat strains?
Differences in HPA axis function and stress responsiveness 
can contribute to varying severity of inflammation (Dhabhar, 
2002). Morphine activates the HPA axis (Pechnick, 1993), 
which in turn via its inherent role in pain modulation and 
immune function has been proposed to potentiate morphine 
analgesia (Bodnar & Kest, 2010; Kosten & Ambrosio, 2002; 
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Mellon & Bayer, 1998; Woolfolk & Holtzman, 1995). 
However, this is unlikely to have contributed to the acute an-
tinociceptive actions of morphine in the hot plate study due 
to the transient nature of the thermal stimulus applied, and as 
supported by the lack of treatment effects on plasma corticos-
terone levels. We cannot exclude a role of HPA axis activa-
tion in potentiation of morphine efficacy and potency in LEW 
rats after tonic inflammatory injury. However, commensurate 
changes were not observed in the stress- sensitive F344 strain, 
and the corticosterone levels for morphine- treated LEW and 
F344 rats were markedly less than measured in Crl:SD rats. 
Accordingly, any putative contribution of strain- dependent 
stress reactivity to analgesic effects of morphine, or indeed 
other drug candidates in pain assays such as those used here 
is undoubtedly complex.
Linking the temporal pharmacodynamic actions of a drug 
candidate, here exemplified by the mu opioid receptor mor-
phine, to relevant concentrations within its target tissue(s) is 
a highly desirable facet of demonstrating appropriate target 
engagement in drug discovery. In this regard, a potential 
limitation of our study was the use of a single 60 min time 
point post- morphine for assessment of efficacy. Whereas the 
analgesic effects of morphine in rodent assays of acute no-
ciception are mediated centrally, both peripheral and central 
sites contribute to its anti- hyperalgesic efficacy in inflam-
matory models (Schafer et al., 1995; Zhang et al., 2003). 
Accordingly, Tmax for s.c. morphine is reached more rapidly 
in plasma (0.25 hr = 15min) than in brain where it ranges 
from 45 to 95 min (Stain et al., 1995; Van Crugten, Somogyi, 
& Nation, 2000), which aligns well with the efficacy time 
point used here. When combined with other reports for LEW 
and F344 rats describing antinociceptive effects of morphine 
peaking at 30–60 min (Cook et al., 2000), and similar Cmax 
in blood at this time (Davis et al., 2007), we think it unlikely 
that pharmacokinetic differences are responsible for the clear 
strain differences in morphine antinociception observed in 
our hot plate experiments; observations further supported 
by the comparable strain effects of morphine in both CFA- 
and locomotor- studies. These findings do not however con-
sider accumulation of morphine or its metabolites within 
the CNS, where enhanced analgesic effects of morphine in 
Spontaneously Hypertensive Rats compared with WKY rats 
(their normotensive controls) have been linked to higher 
tissue concentrations within spinal cord and various brain 
areas, despite similar plasma pharmacokinetic parameters 
(Bhargava et al., 1992; Gulati & Bhargava, 1990).
Can other mechanisms account for the differences in 
analgesic efficacy of morphine between strains? Although 
comparative insights typically need to be gained from stud-
ies which have been performed in isolation, a number of 
possibilities may exist. Despite possessing a similar density 
of mu- opioid receptors in brain and spinal cord (Herradon, 
Morales, & Alguacil, 2003; Herradon, Morales, Perez- Garcia 
et al., 2003), the intrinsic responsiveness of the receptor and 
its downstream signalling cascades to agonist stimulation 
differs between F344 and LEW rats even in the absence of 
injury (Guitart et al., 1993; Herradon, Morales, & Alguacil, 
2003; Herradon, Morales, Perez- Garcia et al., 2003; Selley 
et al., 2003). Although inflammatory injury of itself fails to 
change receptor affinity to opioid agonists, it does increase 
the density of mu- opioid receptor binding sites and G- protein 
coupling within dorsal root ganglion of Wistar rats (Zollner 
et al., 2003); this likely explains why inflammation poten-
tiates the overall efficacy of morphine in the current study, 
especially in inflammatory- prone LEW rats (Juif et al., 2012; 
O’Malley, Julio- Pieper, O’Mahony, Dinan, & Cryan, 2014; 
Sternberg et al., 1989). Strain differences in nociceptive pro-
cessing are not restricted to models of acute and tonic pain. 
Strain- dependent nociceptive sensitivity has also been re-
ported in various rodent models of neuropathic pain (del Rey 
et al., 2011; Le Coz, Fiatte, Anton, & Hanesch, 2014; Rode 
et al., 2007; Yoon, Lee, Lee, Chung, & Chung, 1999; Zeng 
et al., 2008), wherein a primary pathophysiological mech-
anism involves a change in descending modulatory control 
from brainstem structures (e.g., PAG and RVM) to the spinal 
dorsal horn to facilitate nociceptive transmission (De Felice 
et al., 2011). Intriguingly, a higher incidence of neuropathic 
sensitivity in SD rats versus closely- related outbred Holtzman 
rats (85% vs. 50%, respectively) has been attributed to the 
protective recruitment of descending inhibition in the latter 
strain (De Felice et al., 2011). Notably, despite a myriad of 
side- effects opioids are efficacious in neuropathic pain act-
ing in part by engaging descending monoaminergic pathways 
(Finnerup, Sindrup, & Jensen, 2010). Whether differential 
recruitment of such a mechanism accounts in part for the cur-
rent findings is speculative, although not unreasonable based 
on the acknowledged role of descending modulation to in-
flammatory hyperalgesia (Ren & Dubner, 1996).
6 |  CONCLUSIONS
Using morphine as a candidate analgesic, our data reflect that 
reliance on a single strain of rat, behavioural assay, even ven-
dor, for purposes of assessing efficacy is not straightforward. 
A key question that arises is whether a specific strain possess 
superior translational utility in pain research over others? We 
are not aware of any overriding evidence supporting the use 
of commonly used outbred rat strains such as SD or Wistar in 
this regard, albeit as noted above they may develop a greater 
degree of neuropathic hypersensitivity compared with other 
strains (De Felice et al., 2011). Researcher compliance may 
also be influenced by an anecdotal assumption that the het-
erogenic diversity of such outbred strains better reflects 
that of a typical pain patient cohort. Rather, pragmatic is-
sues such as reproductive fecundity and availability, ease of 
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animal handling, unit costs and adherence to previously pub-
lished methodologies appear to guide researcher compliance 
(Festing, 2014). Ultimately, we believe that comparative 
studies such as ours are crucial for facilitating future discus-
sion and mitigation of data discrepancy within analgesic drug 
research and development.
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